Thomas Waldmann

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Survival adjustment of mature dendritic cells by IL-15
    Sigrid P Dubois
    Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 102:8662-7. 2005
  2. pmc Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 121:476-84. 2013
  3. ncbi request reprint The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 6:595-601. 2006
  4. ncbi request reprint IL-15 in the life and death of lymphocytes: immunotherapeutic implications
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute National Institutes of Health, Bethesda, MD 20892 1374, USA
    Trends Mol Med 9:517-21. 2003
  5. ncbi request reprint Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH Building 10, Bethesda, Maryland 20892 1374, USA
    J Clin Immunol 27:1-18. 2007
  6. ncbi request reprint Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma
    T A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1374, USA
    Oncogene 26:3699-703. 2007
  7. ncbi request reprint ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters
    Thomas Waldmann
    National Institutes of Health, National Cancer Institute, Bldg 10, Room 4N115, 10 Center Drive 1374, Bethesda, MD 20892 1374, USA
    Leuk Lymphoma 44:S107-13. 2003
  8. ncbi request reprint Immunotherapy: past, present and future
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 9:269-77. 2003
  9. ncbi request reprint The use of antibodies against the IL-2 receptor in transplantation
    T A Waldmann
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Opin Immunol 10:507-12. 1998
  10. ncbi request reprint Effective cancer therapy through immunomodulation
    Thomas A Waldmann
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1374, USA
    Annu Rev Med 57:65-81. 2006

Detail Information

Publications67

  1. pmc Survival adjustment of mature dendritic cells by IL-15
    Sigrid P Dubois
    Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 102:8662-7. 2005
    ..These findings support the hypothesis that DCs mediate the effect of IL-15 on CD8+/CD44(hi) memory phenotype T cells...
  2. pmc Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 121:476-84. 2013
    ....
  3. ncbi request reprint The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 6:595-601. 2006
    ..As discussed in this Review, the biology of these cytokines will affect the development of novel therapies for malignancy and autoimmune diseases, as well as the design of vaccines against infectious diseases...
  4. ncbi request reprint IL-15 in the life and death of lymphocytes: immunotherapeutic implications
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute National Institutes of Health, Bethesda, MD 20892 1374, USA
    Trends Mol Med 9:517-21. 2003
  5. ncbi request reprint Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH Building 10, Bethesda, Maryland 20892 1374, USA
    J Clin Immunol 27:1-18. 2007
    ....
  6. ncbi request reprint Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma
    T A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1374, USA
    Oncogene 26:3699-703. 2007
    ..These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma...
  7. ncbi request reprint ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters
    Thomas Waldmann
    National Institutes of Health, National Cancer Institute, Bldg 10, Room 4N115, 10 Center Drive 1374, Bethesda, MD 20892 1374, USA
    Leuk Lymphoma 44:S107-13. 2003
    ....
  8. ncbi request reprint Immunotherapy: past, present and future
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 9:269-77. 2003
  9. ncbi request reprint The use of antibodies against the IL-2 receptor in transplantation
    T A Waldmann
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Opin Immunol 10:507-12. 1998
    ..In a randomized trial, when added to standard cyclosporin-based immunosuppression, daclizumab significantly reduced the frequency of acute rejection of renal transplants...
  10. ncbi request reprint Effective cancer therapy through immunomodulation
    Thomas A Waldmann
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1374, USA
    Annu Rev Med 57:65-81. 2006
    ....
  11. ncbi request reprint The meandering 45-year odyssey of a clinical immunologist
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC 1374, Building 10, Room 4N115, Bethesda, Maryland 20892 1374, USA
    Annu Rev Immunol 21:1-27. 2003
    ..New forms of therapy directed at IL-2 and IL-15 receptors may be effective against certain neoplastic diseases and autoimmune disorders and in the prevention of allograft rejection...
  12. ncbi request reprint The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens
    T A Waldmann
    Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Annu Rev Immunol 17:19-49. 1999
    ..New approaches directed toward IL-15, its receptor, or its signaling pathway may be of value in the therapy of these disorders...
  13. pmc The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases
    Thomas Waldmann
    Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Arthritis Res 4:S161-7. 2002
    ..New approaches directed toward inhibiting the actions of the inflammatory cytokine, IL-15, are proposed for an array of autoimmune disorders including rheumatoid arthritis as well as diseases associated with the retrovirus HTLV-I...
  14. pmc Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
    Thomas A Waldmann
    Center for Cancer Research, National Cancer Institute, Frederick, MD, USA
    Blood 117:4787-95. 2011
    ....
  15. pmc A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease
    Ronald R Buggage
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892 1857, USA
    Ocul Immunol Inflamm 15:63-70. 2007
    ..To investigate the safety and efficacy of daclizumab (Zenapax, humanized anti-Tac, HAT) in controlling the ocular manifestations of Behçet's disease...
  16. pmc Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia
    John C Morris
    Metabolism Branch, Center for Cancer Research, and Office of Cancer Complementary and Alternative Medicine, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:401-6. 2006
    ....
  17. ncbi request reprint Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein
    Vladimir S Talanov
    Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Nucl Med Biol 33:469-80. 2006
    ..The in vivo studies also revealed that the N-methyl modification resulted in a superior statinated product...
  18. pmc Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:5941-6. 2006
    ..This immunoregulation has potential importance for the treatment of autoimmune diseases and transplant rejection and toward modification of tumor immunity...
  19. ncbi request reprint Detection of receptor trimers on the cell surface by flow cytometric fluorescence energy homotransfer measurements
    Laszlo Bene
    Department of Biophysics and Cell Biology, Medical and Health Science Center, Research Center for Molecular Medicine, University of Debrecen, Hungary
    Biochim Biophys Acta 1744:176-98. 2005
    ....
  20. pmc Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25
    Zhuo Zhang
    Metabolism Branch, NCI, NIH, Bldg 10, Room 4N115, 10 Center Drive, Bethesda, MD 20892 1374, USA
    Blood 108:1007-12. 2006
    ..These results that demonstrate a significantly improved therapeutic efficacy by combining (211)At-7G7/B6 with daclizumab support a clinical trial of this regimen in patients with ATL...
  21. pmc Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute, National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 102:9571-6. 2005
    ..Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of T(CM) may be superior to T(EM)/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination...
  22. pmc Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle
    Hisataka Kobayashi
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1088, USA
    Neoplasia 7:984-91. 2005
    ....
  23. pmc Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors
    Meili Zhang
    Metabolism Branch, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 108:705-10. 2006
    ..We demonstrated that the expression of FcRgamma on polymorphonuclear leukocytes and monocytes was not required for HeFi-1-mediated tumor growth inhibition in vivo, although it was required for daclizumab...
  24. pmc ITK and IL-15 support two distinct subsets of CD8+ T cells
    Sigrid Dubois
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:12075-80. 2006
    ..Thus, whereas ITK-dependent CD44(lo)CD122(lo) CD8(+) T cells appear to represent conventional CD8(+) T cells, IL-15-dependent CD44(hi)CD122(hi) CD8(+) T cells may have functions in both adaptive and innate immunity...
  25. pmc The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells
    Noriko Sato
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 104:588-93. 2007
    ....
  26. ncbi request reprint The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia
    Meili Zhang
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1374, USA
    Cancer Res 66:8227-32. 2006
    ..In summary, (211)At-7G7/B6 could serve as an effective therapeutic agent for patients with CD25-expressing leukemias...
  27. pmc IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease
    Fumi Miyagawa
    Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 181:1109-19. 2008
    ....
  28. doi request reprint Receptor-directed therapy of T-cell leukemias and lymphomas
    John C Morris
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Mark O Hatfield Clinical Research Center, Bethesda, Maryland 20892 1457, USA
    J Immunotoxicol 5:235-48. 2008
    ..The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed...
  29. pmc IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells
    Masaki Terabe
    Vaccine Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20893, USA
    J Immunol 180:7276-86. 2008
    ..1(+) T cell subset, CD8alphaalphaNK1.1(+) T cells, and that IL-15-transgenic mice may be a useful resource for studying the functional relevance of CD8(+)NK1.1(+) T cells...
  30. pmc IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis
    SangKon Oh
    Vaccine Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
    Proc Natl Acad Sci U S A 105:5201-6. 2008
    ..These findings suggest new vaccine strategies against infections and cancers, especially in individuals with CD4-deficiency...
  31. doi request reprint Nanometer-scale organization of the alpha subunits of the receptors for IL2 and IL15 in human T lymphoma cells
    Bärbel I de Bakker
    Applied Optics Group, Faculty of Science and Technology, MESA Research Institute for Nanotechnology, University of Twente, PO Box 217, 7500 AE Enschede, The Netherlands
    J Cell Sci 121:627-33. 2008
    ..Our results should aid understanding the action of the IL2R-IL15R system in T cell function and also might contribute to the more rationale design of IL2R- or IL15R-targeted immunotherapy agents for treating human leukemia...
  32. ncbi request reprint Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action
    Sigrid Dubois
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 180:2099-106. 2008
    ..Thus, a preassociation with IL-15Ralpha-IgG1-Fc enhances the activities of IL-15 in vivo and in vitro that may be useful in the treatment of tumors...
  33. pmc Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies
    Matthew K Robinson
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 14:875-82. 2008
    ..We hypothesized that the C6.5 diabody, a noncovalent anti-HER2 single-chain Fv dimer, would be an ideal radioisotope carrier for the radioimmunotherapy of established tumors using the short-lived alpha-emitting radioisotope (211)At...
  34. pmc Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice
    Liyanage P Perera
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bldg 10, Bethesda, MD 20892 1374, USA
    J Virol 81:8774-83. 2007
    ..Thus, Wyeth IL-15 and MVA IL-15 viruses hold promise as more-efficacious and safe alternatives to the Dryvax vaccine...
  35. pmc Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1
    Meili Zhang
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, PET Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 104:8444-8. 2007
    ..001). In summary, radiolabeled HeFi-1 is very promising for the treatment of CD30-expressing leukemias and lymphomas, and the combination regimen of (211)At-HeFi-1 with unmodified HeFi-1 enhanced the therapeutic efficacy...
  36. ncbi request reprint A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
    John C Morris
    Metabolism Branch, Laboratory of Pathology, Department of Laboratory Medicine, National Eye Institute, Bethesda, MD 20892 1457, USA
    Clin Cancer Res 13:958-64. 2007
    ..The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points...
  37. ncbi request reprint Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins
    Vladimir S Talanov
    Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Nucl Med Biol 31:1061-71. 2004
    ..Formation of 11, however, is found to require the absence of NCS. Elimination of acetic acid is found to have no effect on radiolabeling efficiency or yield for either of these reactions...
  38. ncbi request reprint Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation
    Hisataka Kobayashi
    Metabolism Branch, Radiation Biology Branch, and Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1002, USA
    Clin Cancer Res 10:7712-20. 2004
    ..Such information might be applied to optimize the efficacy of subsequent or concurrent therapies including radiolabeled antibodies or other anticancer agents in combination with external beam therapies...
  39. ncbi request reprint Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration
    Robert B Nussenblatt
    The National Eye Institute, Laboratory of Immunology, NIH, Building 10, 10 Center Drive, Bethesda, MD, USA
    J Autoimmun 21:283-93. 2003
    ..These studies suggest that anti-IL-2 receptor blockade could be useful in the treatment of Th1-mediated autoimmune conditions...
  40. ncbi request reprint Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H
    Zhuo Zhang
    Metabolism Branch, Center for Cancer Research, National Cancer Institute NIH, Building 10, Room 4N115, 10 Center Drive, Bethesda, MD 20892 1374, USA
    Cancer Res 63:6453-7. 2003
    ..This study provides support for a clinical trial of Campath-1H in the treatment of patients with T-cell leukemias and lymphomas...
  41. ncbi request reprint Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1374, USA
    Magn Reson Med 50:758-66. 2003
    ..In conclusion, DAB-G5 and PAMAM-G4 can be used to identify lymph nodes and lymphatic vessels, respectively. Their rapid excretion makes these compounds potentially attractive for human use...
  42. ncbi request reprint Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Bioconjug Chem 14:1044-7. 2003
    ..Moreover, it permits the repeated injection of the contrast agent and the "avidin switch" during a single MR experiment...
  43. ncbi request reprint Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507
    Zhuo Zhang
    Metabolism Branch, Center for Cancer Research, National Cancer Institute NIH, Bldg 10, Rm 4N115, 10 Center Drive, Bethesda, MD 20892 1374, USA
    Blood 102:284-8. 2003
    ..These results demonstrate that MEDI-507 has therapeutic efficacy on ATL in vivo and provides support for a clinical trial involving this monoclonal antibody in the treatment of patients with CD2-expressing leukemias and lymphomas...
  44. pmc Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity
    SangKon Oh
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:3392-7. 2003
    ....
  45. pmc Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
    Meili Zhang
    Metabolism and Radiation Oncology Branches, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1374, USA
    Proc Natl Acad Sci U S A 100:1891-5. 2003
    ..Thus, Pretarget radioimmunotherapy is very promising and could represent the next generation in the treatment of lymphoma and leukemia...
  46. ncbi request reprint Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 63:271-6. 2003
    ....
  47. ncbi request reprint Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin
    Zhengsheng Yao
    Nuclear Medicine Department of the Warren G Magnuson Clinical Center, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:5755-60. 2002
    ....
  48. ncbi request reprint Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates
    Raya Mandler
    Metabolism Branch, National Cancer Institute, NIH, Bethesda, Maryland 20982 1002, USA
    Bioconjug Chem 13:786-91. 2002
    ..However, unlike H:ABA-GA, the immunoconjugate H:APA-GA caused stable tumor regression (in 25% of the recipients), showing a qualitative improvement with potential clinical relevance...
  49. ncbi request reprint Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213
    Meili Zhang
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 100:208-16. 2002
    ..The findings of this study support the use of this combination approach in a clinical trial in patients with IL-2R alpha-expressing leukemias...
  50. ncbi request reprint Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia
    Chalet Tan
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1374, USA
    Cancer Res 62:1083-6. 2002
    ....
  51. ncbi request reprint GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia T cell lines
    Janos Matko
    Department of Biophysics and Cell Biology, Cell Biophysics Research Group of the Hungarian Academy of Sciences, University of Debrecen, Health Science Center, Debrecen, Hungary
    Eur J Biochem 269:1199-208. 2002
    ..g. CD48). Based on these data, the integrity of these GPI-microdomains seems critical in signal transduction through the IL-2R complex...
  52. pmc Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells
    Sigrid Dubois
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:14169-74. 2003
    ..Thus, IL-15 induces T cell proliferation mainly via FKBP12-mediated p70S6K activation. In contrast, IL-2 signaling involves multiple pathways that include at least one additional pathway that depends on FKBP12.6...
  53. ncbi request reprint Interleukin-2 receptor-directed therapies for cutaneous lymphomas
    Francine M Foss
    Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Hematol Oncol Clin North Am 17:1449-58. 2003
    ....
  54. pmc IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells
    SangKon Oh
    Vaccine Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:15154-9. 2004
    ..Conversely, high-avidity CTLs are diminished in IL-15Ralpha knockout mice. These results provide an explanation of CD8+ T cell avidity maturation and may contribute to the design of novel vaccines...
  55. ncbi request reprint Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody
    Meili Zhang
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg 10, Rm 4N115, 10 Center Dr, Bethesda, MD 20892, USA
    Blood 105:1231-6. 2005
    ..01). The significantly improved therapeutic efficacy by combining flavopiridol with HAT provides support for a clinical trial in the treatment of ATL...
  56. ncbi request reprint Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 105:721-7. 2005
    ..Furthermore, our observation provides the scientific basis for a novel strategy to prevent cancer development/metastasis...
  57. ncbi request reprint Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia
    Meili Zhang
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1374, USA
    Cancer Res 64:5825-9. 2004
    ..Although NK cells may play a role in humans, in this murine model FcRgamma receptors on non-NK cells, such as polymorphonuclear leukocytes or monocytes, are required for the tumor-killing action of the antibodies directed toward CD25...
  58. pmc IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells
    György Vámosi
    Cell Biophysics Research Group of the Hungarian Academy of Sciences, Debrecen, Hungary
    Proc Natl Acad Sci U S A 101:11082-7. 2004
    ..In addition, both alpha-chains were at least partially homodimerized/oligomerized, which could be the basis of distinct signaling pathways by the two cytokines...
  59. pmc Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases
    Thomas A Waldmann
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Arthritis Res Ther 6:174-7. 2004
    ....
  60. ncbi request reprint Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma
    John E Janik
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 104:3355-7. 2004
    ..Serum sIL-2R levels were elevated in both patients with recurrent disease...
  61. ncbi request reprint Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin
    Zhengsheng Yao
    Department of Nuclear Medicine, Warren G Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3137-46. 2004
    ..This study investigated the biodistribution of bismuth-labeled biotin in A431 tumor-bearing mice pretargeted with antibody B3-streptavidin (B3-SA) and examined the therapeutic efficacy of the alpha emitter, (213)Bi-labeled biotin...
  62. ncbi request reprint Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1374, USA
    J Natl Cancer Inst 96:703-8. 2004
    ..Improving current magnetic resonance (MR) imaging methods using a newly synthesized nano-size paramagnetic molecule, G6, as a contrast agent, provides an attractive means toward attaining this goal...
  63. ncbi request reprint Micro-MRI methods to detect renal cysts in mice
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Kidney Int 65:1511-6. 2004
    ....
  64. ncbi request reprint Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At
    Jon N Wesley
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Nucl Med Biol 31:357-64. 2004
    ..7+/-2.4 days survival (p<0.001 versus controls) with (211)At labeled HAT. Thus, (211)At labeled HAT may have application in organ transplantation and in treatment of IL-2 receptor expressing T-cell leukemia...
  65. ncbi request reprint Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity
    Raya Mandler
    Metabolism Branch, Center for Cancer Research, National Cancer Institute NIH, 6701 Rockledge Drive, Room 5217, MSC 7840, Bethesda, MD 20892, USA
    Cancer Res 64:1460-7. 2004
    ..In addition, the chemical linkage and the considerations in therapeutic regimen described here could be applied to other immunoconjugates for targeted therapy of a broad spectrum of cancers...
  66. pmc IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 101:1969-74. 2004
    ..These results provide several avenues for improving adoptive immunotherapy of cancer in patients...
  67. ncbi request reprint Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications
    Meyoung Kon Kim
    Department of Nuclear Medicine, Warren G Magnuson Clinical Center, Bethesda, Maryland 20892, USA
    Nucl Med Biol 29:139-46. 2002
    ..3% ID/g for 99mTc-MAG3-Fab, whereas the glycolation resulted in a drastic reduction of the renal uptake at 15 min. We demonstrated that the renal clearance and the tumor targeting of Fab could be optimized by chemical modifications...